Eli Lilly says oral GLP-1 Foundayo lowers predicted diabetes and heart risk
Lilly said an analysis found its oral GLP-1 Foundayo was associated with reduced predicted long-term risk of type 2 diabetes and heart disease in adults with obesity.
Lilly said an analysis found its oral GLP-1 Foundayo was associated with reduced predicted long-term risk of type 2 diabetes and heart disease in adults with obesity.